

Date: 07-08-2026

To
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

Ref: BSE Scrip Code: 533259; NSE Symbol: HEALTHX

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached herewith the Investor Presentation of the Company.

This is for your information and record.

Thanking you,
Yours faithfully,

For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

Pratap Singh
Company Secretary & Compliance Officer
M. No.: A24081

Encl: As above



“**Health X** is India’s AI-powered digital health platform- making **medicines, wellness** and **diagnostics accessible, affordable, and trustworthy** from the busiest city to the last village”

Health X Platform Limited

(erstwhile Sastasundar Ventures Limited)

August 2026

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Health X Platform Limited (erstwhile Sastasundar Ventures Limited) (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Key Highlights at a Glance

	01 High Revenue Growth Continuous		
	Sustained top-line momentum across all channels.	Q-o-Q ▲ 16 %	Y-o-Y ▲ 47 %
	02 Expanding Gross Margin		
	Gross Margin widening on better sourcing, private-label mix and channel optimisation.		
	2A June -26 vs March-26	Current Qtr 7.9%	Comparative Quarter 7.5 % Change ▲ 40 bps
	2B June -26 vs June-25	7.9 %	6.6 % ▲ 130 bps
	03 Operating Leverage – Revenue Vs Opex Cost		
	Opex falling as a % of revenue; EBIT margin expanding towards Gross Margin as the fixed-cost base is absorbed by scale.		
	3A June -26 vs March-26	Current Qtr 11.6 %	Comparative Quarter 13.3 % Change ▼ 170 bps
	3B June -26 vs June-25	11.6 %	11.0 % ▲ 60 bps
	04 Minimal Depreciation & Finance Cost		
	Asset-light, low-leverage model keeps Depreciation and finance cost a small share of revenue.	(Depreciation + Finance Cost) / Revenue 0.7 %	
	05 Working Capital Efficiency		
	Disciplined receivables, inventory and payables cycle drives strong cash conversion.	Net working-capital days 28 days	

Q-o-Q compares the Quarter June-26 with Quarter March -26; Y-o-Y compares the Quarter June-26 with Quarter June -25)

*Growth, Gross Margin and Operating Leverage is excluding Financial Services revenue.

Philosophies of Capital Allocation

Warren Buffett - Real Earnings, Real Discipline

- Distrusts EBITDA - it ignores real, unavoidable costs like Depreciation
- Measures success through owner earnings: net income (+) Depreciation and Amortisation (-) the capex needed to stay competitive.
- Prizes sustained, low-leverage ROE — capital efficiency proven over decades, not one good quarter

Jeff Bezos - Cash flow and Long-term Compounding

- Prioritizes free cash flow per share over reported GAAP profit as the true measure of value
- Willingly deferred ROCE for years — running thin margins to fund the flywheel
- Reinvested nearly all operating cash into infrastructure, logistics, and new bets to build durable market position

HealthX: Where Discipline Meets Patience

“Built on Buffett’s discipline of real, capital-efficient earnings- combined with Bezos’s patience to reinvest in the technology, brand, and infrastructure that earns India’s trust in healthcare”.

Discipline:


A capital - efficient, real - earnings mindset across **SastaSundar** and **RetailerShakti** - every rupee of capital held to account.

Patience:



Sustained reinvestment in technology, brand & infrastructure -- building the trust that compounds into long-term market position.

The HealthX Ecosystem — X-Factor

healthX
Innovate. Heal. Thrive.



SastaSundar app
health & happiness



Retailer Shakti
Stock ka Wada, Margin Zyada

SastaSundar app

health & happiness

Health & Happiness

B2C PLATFORM

Genuine medicines, wellness & diagnostics
with real savings, convenience & happiness.



Wide
Range



Best
Prices



100%
Genuine



Easy
Returns



Fast
Delivery



Retailer Shakti

Stock ka Wada, Margin Zyada

B2B PLATFORM

Empowering pharmacies & retailers with
more margin, complete stock & trust.



Higher
Margins



Complete
Stock Availability



100%
Genuine



Fast & Reliable
Delivery



Dedicated
Support



One Mission.

Two Powerful Platforms.

Better Health for **Every** Indian.



Our Core Operating Capabilities



One Integrated Platform:

Controlling sourcing, storage, movement, healthtech enablement and last mile delivery

Our Unique Advantages: Unmatched Efficiency & Reach

Key capabilities that power our growth-oriented platform



Capital & Cost Efficiency

Lowest cost of operations;
highest capital efficiency



Reach from Tier 1 Cities to Remote Villages

Profitable delivery across
all geographies



Exceptional Consumer Experience

Fast, reliable, and affordable
solutions



Positive Economics for Every Order

Serving all customers,
even smallest orders



Delivering the most efficient, broadest-reaching, and cost-effective healthcare

X-Factors for Consumers

Delivering exceptional value in healthcare solutions



**100% Authentic
Products & Services**



**Counseling
& Health Informations**



**Personalized Services
Using Data & AI**



**Maximum
Discounts**



**Complete Order
Fulfillment**



**Shop-in-Shop for
Quality Generics**



**Wide Variety of
Wellness Products**



**Promise Delivery
Every Time**

Value Creation for Retail Pharmacies

healthX
Innovate. Heal. Thrive.



Reliable fulfillment of all
medicine needs.



Clear discounts and
schemes, transparent price



Better margins
instead of credit



Simple return process
for unsold/high inventory



Helps reducing
inventory levels



Trusted Quality. Transparent Savings



1000+
Healthcare
SKUs



Quality
You Can
Trust



Healthcare
for Every
Indian



Accessible
Across
India

WHY CHOOSE JITO?



Same active ingredients
as leading brands



Better affordability for
long-term treatment



Comparable therapeutic
outcomes



Committed to quality,
transparency & trust

SAVINGS PROOF OF JITOATOR 20

MRP

₹107

(Inclusive of all taxes)

DISCOUNT

60%

OFF

PURCHASE PRICE

₹42.80

Per Strip

₹4.28 / Tablet* (Inclusive of all taxes)

**SAVINGS THAT MAKE
A DIFFERENCE**



Monthly savings for chronic
users can be significant



Enables long-term adherence
without financial burden

QUALITY & TRUST ASSURANCE



WHO-GMP

Manufactured in
**WHO-GMP Certified
Facilities**



COA

Supported by
**Certificate of analysis
(COA)**



MC-3205

Tested in
**NABL-Accredited
Laboratories**

EASY ACCESS & AVAILABILITY



SastaSundar app
health & happiness

Order from SastaSundar App and
get it delivered within 24 hrs*.



Scan QR Code
to Download
App



Quality Medicines



Trusted by Doctors



Preferred by Customers



Savings for a Healthier Tomorrow

Affordable generics made widely accessible through digital platforms & Pharmacy partnerships



HEALTH & HAPPINESS PODCAST

Conversations That Inspire Healthier Lives.

Honest Conversations With Doctors, Entrepreneurs, Patients, And Policymakers. Stories From The Frontlines Of Indian Healthcare — Told With Empathy, Rigour, And Purpose.



Delivering **credible** and **transparent** information to society



Enabling **direct** connection with doctors



Strengthening brands through **meaningful** engagement



A powerful platform for **brand building**



A scalable platform for **revenue generation**



Trusted platform empowering viewers through health education and direct access to expert doctors.

Strategic Priorities for next 5 years

Growth CAGR 30%+



Expanding wallet share
of existing customers.



Expanding market
shares by acquiring
new customers.



Penetrating geography
across existing &
fulfilment centers.
(Market Size as per IPM
50,000 Crs)



Opening new
fulfilment centers.
(Market Size as per IPM
46,000 Crs)



Category expansion in
line with products that
is wellness, personal
care and beauty care.



Expanding services
that is diagnostic,
doctor consultation,
quick health.

AI Integration across the value chain



Intelligent medicine &
diagnostic counselling.



Consultation validation
for quality assurance.



Wellness counselling and
personalized
recommendations.



Smart health records
with automated testing
hooks.



Backend process
automation to enhance
productivity.

Profit and Cash flow generation



Revenue Growth.



Gross Margin Expansion



Optimizing operating
cost.




Monetization of digital
property

Growth Track Record

SastaSundar - Pre-FKH


▲ 68%



	2014-15	2020-21
Sales (in Crs)	21	474
CAGR*		68%

SastaSundar - During FKH


▼ 35%



	2021-22	2024-25
Sales (in Crs)	510	135
CAGR*		35%

SastaSundar - Post-FKH

▲ 64%



	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Sales (in Crs)	26	32	42	44	44	48
CAGR*						64 %


Despite recent growth volatility during the partnership with Flipkart, the company successfully leveraged this transition as a strategic opportunity to regain full control. Following Flipkart's decision to streamline its healthcare operations, the partnership ended, resulting in the cessation of Flipkart Health+ as an associate company in FY25. By transitioning from a 25% minority stake back to 100% ownership, the company is now fully capitalized and ideally positioned with complete operational control over the SastaSundar platform to drive future scaling.

*CAGR Annualized

Growth Track Record

Retailer Shakti

▲ 96%



	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26
Sales (in Crs)	20	66	113	212	489	950	1125
CAGR							96%


*CAGR Annualized

Capital Efficiency & Working Capital

Total Capital Deployed

<u>Particulars</u>	<u>Amount (₹ in Crs)</u>
Total Capital Raised	352
Cost of Capital (post-tax) @9% p.a XIRR	431
Total Capital deployed with cost of capital	783
Capital Bought back	(100)
Net Capital after Buy Back	683
Treasury in SHBL	(367)
Net assets in SHBL	(194)
Capital deployed in IPR of Business	122

<u>Working Capital</u>	<u>Quarter ended</u>			
<u>Working Capital (No of Days)</u>	<u>Jun-26</u>	<u>Mar-26</u>	<u>Jun-25</u>	<u>Mar-25</u>
Inventory	39	34	36	35
Receivable	3	4	6	7
Payable	14	20	11	19
Working Capital (No of Days)	28	18	32	23
Working Capital % of Revenue	8%	5%	9%	6%
Working Capital ₹ in Crs	128	74	95	73



Key Data Points



Within **24 Hours** Delivery Model
for **90% of orders**



50k+ SKUs from **1000+** Vendors



350+
HealthBuddies



3500+
Employees



75K
Retail Pharmacies



Purchase return (PDRN) **less than 1%**, the lowest in the industry.



More than **95%** Purchase directly
from Pharma companies without
paying a single rupee to purchase
any right.

JITO: FRANCHISE



19

JITO: PIPELINE



25

Changing India.

We are building for the India of the next decade - where distribution consolidates, data leads, and care include preventive.



B2B Consolidation

Distribution consolidates to fewer than 100 national distributors, in line with developed markets.



Distributor Private-Label Brands

A win-win model - better value for the consumer, stronger margins for the distributor.



Data-Driven Omnichannel

A unified, data-led consumer experience across every channel.



AI-Led Behaviour Shift

AI reshapes consumer habits and accelerates technology adoption across distribution.



Inclusive Healthcare

Building healthcare infrastructure across all income levels and all geographies



Rise of Preventive Care

Preventive-care products capture a growing share of the healthcare basket.

Geographic Footprint: A Proven Model from Tier 1 to Rural

For the Quarter ended Jan-Mar-26	<u>Retailer Shakti</u>	
Areas	Sales Value (Rs in cr)	Weighted average (%)
Tier 1 (Urban Area)	105.8	33.1%
Tier 2 (Semi Urban Area)	134.9	42.2%
Tier 3 (Rural Area)	79.2	24.8%
Total Sales	319.9	100.0%

For the Quarter ended Jan-Mar-26	<u>SastaSundar</u>	
Areas	Sales Value (Rs in cr)	Weighted average (%)
Tier 1 (Urban Area)	11.0	22.2%
Tier 2 (Semi Urban Area)	22.7	45.5%
Tier 3 (Rural Area)	16.0	32.3%
Total Sales	49.7	100.0%

1. **Market Versatility:** The data demonstrates a balanced revenue mix, proving the platform's adaptability to both high-density Tier 1 markets and logistics-heavy Tier 3 regions.
2. **Deep Rural Inclusion:** Over **77.8% of SS business** and **67% of RS business** is driven by Tier 2 and Tier 3 markets, validating our core mission of democratizing healthcare access beyond metros.
3. **Optimized Distribution:** While RS maintains a strong urban stronghold (33% in Tier 1), the **significant footprint in Semi-Urban and Rural areas** showcases our robust supply chain capability in "last-mile" connectivity.
4. **Scalability:** This geographic distribution confirms a scalable model that is **not dependent on a single demographic**, mitigating regional economic risks.

Built to Profitably Serve Even the Smallest Order

RETAILER SHAKTI (RS)

<u>Range*</u>	<u>RS in %</u>
Upto Rs 1000	2.5%
Rs 1001-2500	28.1%
Rs 2501-5000	27.0%
Rs 5001-10000	22.9%
Above 10000	19.5%
Total	100.0%

SASTASUNDAR (SS)


<u>Order Range*</u>	<u>SS in %</u>
Upto Rs 500	12.4%
Rs 501-1000	18.4%
Above 1001	69.2%
Total	100.0%

**based on Jan-March 2026 Sales Data*

1. **High-Value Dominance:** Over **42.40% of Retailer Shakti (RS)** business is concentrated order over and above ₹5,000, reflecting deep customer trust and significant logistical efficiency.
2. **B2B Efficiency (Retailer Shakti):** With **69.4%** of business coming from range above ₹2,500, RS demonstrates a highly efficient B2B model where retailers consolidate their requirements, leading to better operational margins.
3. **Balanced Order Mix (SastaSundar):** The SS model showcases a healthy, diversified distribution, with **69.2% of total orders** exceeding the ₹1,001 threshold, indicating a robust and consistent consumer basket size.
4. **Strategic Frequency Funnel:** The **30.8% of SS orders** under ₹1000 reflects our deep market reach and **success in capturing high-frequency daily healthcare needs**, serving as a high-velocity acquisition tool that integrates new and existing users into our ecosystem.
5. **Outcome:** The concentration in higher value ranges provides a **"protective cushion"** against the high costs associated with small-ticket logistics, ensuring a sustainable path to profitability.

India's Largest Pharma Fulfillment Centre powering the profitable growth

The areas coloured in Red shows our current areas of operation.
The mark "FC" signifying "Fulfillment Centres", shows our location of current FCs and the mark "P" shows the location of our planned new FC.



Warehouses	Existing Capacity (Sq. Ft. Approx.)	Additional Capacity
West Bengal	1,56,000	80,000
Noida	39,500	100,000
Guwahati	25,800	75,000
Lucknow (New FC)		75,000
Udaipur (New FC)		75,000
Patna (New FC)		1,00,000
Total	2,21,300	5,05,000

-  Automated with AI-led picking, sorting & routing.
-  Driving lower manpower cost and higher throughput
-  Maximum delivery within 24 hours.

OUR FOUNDERS

Visionary leaders who built a legacy of trust, innovation and impact

healthX
Innovate. Heal. Thrive.



Mr. B.L. Mittal

Executive Chairman, Managing Director
and Chief Executive Officer,
Founding Member

Mr. B.L. Mittal is the founder of healthcare digital platforms **SastaSundar** and **RetailerShakti**, as well as wealth management firms **Microsec** and **Club Kautilya**.



A Fellow Member of:

- The Institute of Chartered Accountants of India
- The Institute of Company Secretaries of India
- The Institute of Cost Accountants of India



He brings over **30 years** of experience in building innovative and impactful businesses across healthcare, finance and digital ecosystems.



His entrepreneurial journey is closely aligned with his philanthropic vision through initiatives such as **Tree Campus Academy** and the **Microsec Foundation**.



He is also an author, sharing insights inspired by Marwari wisdom. His philosophy is rooted in "**Being Genuine**" and "**Being Child**," reflecting authenticity, curiosity, and a commitment to creating a meaningful impact.



LinkedIn Profile:
<https://www.linkedin.com/in/blmittal/>



Mr. Ravi Kant Sharma

Non-Executive Director,
Founding Member

Mr. Ravi Kant Sharma, a Fellow Member of the Institute of Chartered Accountants of India, is a seasoned leader with over **30 years** of experience across financial services and healthcare platforms.



He co-founded the financial services enterprise with Mr. B.L. Mittal in 2000 and has been instrumental in scaling it into a **2,900+** strong organization.



Known for his analytical acumen and strong emotional intelligence, he brings a balanced leadership approach that blends strategic thinking with people-centric management.



His ability to drive growth while fostering organizational cohesion has been central to the company's sustained success and cultural strength over the years.



LinkedIn Profile:
<https://in.linkedin.com/in/ravi-kant-sharma-sastasundar-founder-ceo>

LEADERSHIP TEAM



Vikash Somani

National Head: Operations



Qualifications:
MBA, CFA, M.com



Experience:
20+ years of experience in supply chain, efficient inventory management & planning



Mahesh Singhi

Chief Revenue Officer



Qualifications:
B.Com (H)



Experience:
20+ years of experience with deep expertise in building omni channel, end to end execution across marketing & strategy.



Pankaj Sharma

National Head: Logistics



Qualifications:
B.Com (H)



Experience:
25+ Years in corporates as HEAD of franchisee business with deep expertise in mobility and last mile delivery



Vinay Khaitan

Chief Technology Officer (CTO)



Qualifications:
B.Tech



Experience:
Seasoned Tech professional with 27+ years of experience in Technology & Systems



Lokesh Agarwal

Chief Financial Officer (CFO)



Qualifications:
FCA



Experience:
15 years experience in Finance, Taxation and Control.

Q1 FY27 Consolidated Profit & Loss Statement

Particulars (Rs. Crs)	Q1 FY27	Q1 FY26	Y-o-Y	Q4 FY26	Q-o-Q	FY 25-26	FY 24-25	Y-o-Y
Revenue from Operations	440.3	278.5	58.1%	378.1	16.4%	1,305.9	1,088.1	20.0%
Cost of Materials Consumed	406.1	257.6		350.6		1,208.4	1,017.4	
Gross Margin	34.2	20.9	63.9%	27.5	24.2%	97.5	70.7	37.9%
GM %	7.8%	7.5%		7.3%		7.5%	6.5%	
Employee Benefits Expense	27.7	17.3		25.0		84.0	49.8	
Other Expenses	21.4	17.4		23.3		79.0	99.8	
EBITDA	(14.9)	(13.8)		(20.8)		(65.5)	(78.9)	
EBITDA %	(3.4%)	(5.0%)		(5.5%)		(5.0%)	(7.2%)	
Other Income [#]	19.4	45.3		9.4		71.6	82.6	
Depreciation and Amortisation Expense	1.9	1.2		1.9		6.6	5.8	
EBIT	2.6	30.3		(13.4)		(0.4)	(2.1)	
Finance Costs	0.6	0.1		0.5		0.8	0.2	
Exceptional Items	-	-		(1.0)		(1.1)	(190.5)	
PBT	2.0	30.2		(14.8)		(2.4)	(192.8)	
Total Tax Expense/ (Income)	(0.0)	3.6		(1.9)		(0.9)	(70.1)	
Profit/(Loss) for the period/Year	2.0	26.6		(12.9)		(1.4)	(122.7)	
PAT %	0.5%	9.6%		(3.4%)		(0.1%)	(11.3%)	
Share of profit/(loss) from Associate	0.0	0.0		0.0		0.0	(10.8)	
Profit/(Loss) for the period/Year	2.0	26.6		(12.9)		(1.4)	(133.5)	

[#] Other Income includes financial service income


Breakup of Revenue (Vertical)

Particulars (Rs. Crs)	Q1 FY27	Q1 FY26	Q4 FY26	FY26	FY25
Supply chain					
*SastaSundar	48.1	33.3	44.45	155.5	143.7
Retailer Shakti	361.9	244.5	310.5	1,125.4	941.3
Diagnostics	0.7	0.7	0.4	2.2	3.1
Healthcare Network	410.7	278.5	355.4	1,283.1	1,088.1
Financial Services	49.0	45.3	32.1	94.4	82.6
Total Revenue	459.7	323.8	387.5	1,377.5	1,170.7


**The entire revenue is in the nature of one segment. The bifurcation is given to indicate orders of respective platform. Sastasundar platform being operated by step down subsidiary.*

Annual Financial Highlights

Revenue from Operations



Gross Margin



Historical Consolidated Profit & Loss Statement

Particulars (Rs. Crs)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22
Revenue from Operations	1,305.9	1,088.1	1,355.2	1,036.9	623.0
Cost of Materials Consumed	1,208.4	1017.4	1232.8	960.4	582.5
Gross Margin	97.5	70.7	122.4	76.5	40.5
GM %	7.5%	6.5%	9.0%	7.4%	6.5%
Employee Benefits Expense	84.0	49.8	49.0	45.3	43.9
Other Expenses	79.0	99.8	88.5	78.0	53.7
EBITDA	(65.5)	(78.9)	(15.1)	(46.8)	(57.1)
EBITDA %	(5.0%)	(7.2%)	(1.1%)	(4.5%)	(9.2%)
Other Income [#]	71.6	82.6	81.0	26.5	20.1
Depreciation and Amortisation Expense	6.6	5.8	9.1	8.2	4.2
EBIT	(0.4)	(2.1)	56.7	(28.5)	(41.2)
Finance Costs	0.8	0.2	1.0	0.9	1.6
Exceptional Items	(1.1)	(190.5)	0.0	(8.0)	1,157.5
PBT	(2.4)	(192.8)	55.7	(37.4)	1,114.7
Tax Expense	(0.9)	(70.1)	(36.4)	(22.8)	244.4
PBT before Share of Associate	(1.4)	(122.7)	92.0	(14.6)	870.3
Share from Associate	0	(10.8)	(86.2)	(84.9)	(5.2)
Profit for the year	(1.4)	(133.5)	5.9	(99.5)	865.1
PAT %	(0.1%)	(12.3%)	(0.4%)	(9.6%)	138.9%
EPS	0.37	(28.66)	2.79	(22.70)	197.04

[#] Other Income includes financial service income

Historical Consolidated Balance Sheet

Equity & Liabilities (Rs. Crs)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22
Equity Share Capital	31.8	31.8	31.8	31.8	31.8
Other Equity [#]	733.5	832.7	967.7	961.7	1,062.4
Total Equity	765.3	864.5	999.5	993.5	1,094.2
Non-Financial Liabilities					
(i) Borrowings	0.0	0.0	0.0	0.0	0.0
(ii) Other Financial Liabilities	9.5	5.3	3.3	8.2	3.5
Provisions	8.6	7.2	5.4	4.5	2.1
Tax Liabilities (Net)	5.2	5.4	2.6	24.1	17.9
Deferred Tax Liabilities (Net)	5.4	4.0	67.6	92.5	113.7
Total Non-Financial Liabilities	28.8	21.9	79.0	129.3	137.2
Financial Liabilities					
(i) Borrowings	22.1	0.0	0.0	0.0	0.0
(ii) Lease Liabilities	3.6	0.9	3.9	9.3	1.9
(iii) Trade Payables	86.0	58.8	42.5	57.0	33.0
Other Current Liabilities	30.1	28.3	24.7	16.7	11.5
Total Financial Liabilities	141.7	87.9	71.1	83.0	46.4
Total Equity & Liabilities	935.8	974.4	1,149.6	1,205.8	1,277.8

[#] Other Equity includes non-controlling interest

Assets (Rs. Crs)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22
Property, Plant and Equipment	78.2	63.4	71.6	68.1	57.2
Capital Work-in-Progress	1.2	10.2	0.4	1.0	0.4
Intangibles Assets	0.1	0.1	0.1	0.1	0.1
Goodwill on Consolidation	36.1	36.1	36.1	36.1	36.1
Tax Assets (Net)	10.5	7.1	1.9	4.4	2.3
Deferred Tax Assets	13.7	11.2	0.4	1.8	0.0
Investment Property	2.2	2.3	2.4	2.6	0.0
Other Non-Current Assets	58.3	36.8	34.5	45.8	24.9
Assets classified as held for sale	0.1	0.1	0.0	0.0	0.0
Total Non-Current Assets	200.4	167.3	147.4	159.9	121.0
Inventories	144.6	110.3	115.8	180.8	113.6
Financial Assets					
(i) Investments	518.7	575.4	676.1	512.8	666.0
(ii) Trade Receivable	7.7	10.0	34.8	35.1	21.2
(iii) Cash and Cash Equivalents	30.2	12.4	31.3	31.7	13.0
(iv) Other Bank Balances	0.0	0.0	15.4	163.5	199.4
(v) Loans	9.5	9.0	8.3	8.0	9.6
Other Current Assets	24.7	89.9	120.5	114.0	134.0
Total Current Assets	735.4	807.0	1,002.2	1,045.9	1,156.8
Total Assets	935.8	974.4	1,149.6	1,205.8	1,277.8

Historical Consolidated Cash Flow Statement

Particulars (Rs. Crs)	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22
Cash Flow from Operating Activities					
Profit before Tax	(2.4)	(203.7)	(30.5)	(122.3)	1,109.5
Adjustment for Non-Operating Items	(56.3)	138.1	25.8	84.0	(1,151.0)
Operating Profit before Working Capital Changes	(58.7)	(65.5)	(4.6)	(38.3)	(41.5)
Changes in Working Capital	(10.8)	52.7	46.6	(77.7)	(52.7)
Cash Generated from Operations	(69.5)	(12.9)	42.0	(116.0)	(94.2)
Less: Direct Taxes paid	(4.3)	(4.5)	(6.1)	4.0	(112.9)
Net Cash from Operating Activities	(73.8)	(17.3)	35.9	(112.0)	(207.1)
Cash Flow from Investing Activities	171.2	(1.1)	(33.9)	132.5	219.5
Cash Flow from Financing Activities	(79.6)	(0.4)	(2.4)	(1.8)	(11.4)
Net increase/ (decrease) in Cash & Cash Equivalent	17.8	(18.9)	(0.4)	18.7	1.0
Cash & Cash Equivalents at the beginning of the year	12.4	31.3	31.7	13.0	12.0
Cash & Cash Equivalents at the end of the year	30.2	12.4	31.3	31.7	13.0

‘Being Genuine’ is Our Core Value



Nothing can be more Genuine
than our Mothers' Love

**BEING
GENUINE**

OUR CORE VALUE

We ensure that all our
products and services are
100% Genuine.

SastaSundar.app
health & happiness

Retailer Shakti
Stock ta Wada, Margin Zyada

‘Being Child’ is Our Culture

healthX
Innovate. Heal. Thrive.



**‘BEING
CHILD’**
IS OUR CULTURE

LIKE CHILD-

‘Innovate’, ‘Don’t Discriminate’,
‘Connect Emotionally’ & ‘Grow
Everyday’.

SastaSundar.app
health & happiness

Retailer Shakti
Stock ta Wada, Margin Zyada

For more information reach us at



www.healthxplatform.com



healthX
Innovate. Heal. Thrive.

SastaSundar
health & happiness

Health X Platform Limited
(erstwhile Sastasundar Ventures Limited)

CIN: L65993WB1989PLC047002

Mr. Pratap Singh – Company Secretary
& Compliance Officer

Email Id : investors@sastasundar.com

Thank You

Investor Relations Partner:



Go India Advisors
Unbiased and Balanced

Go India Advisors

Ms. Soumya Chhajed
soumya@goindiaadvisors.com
+91 86197 07750